Avanir Pharmaceuticals (AVNR) in Focus: Stock Moves 6.1% Higher - Tale of the Tape
May 15 2014 - 9:18AM
Zacks
Avanir Pharmaceuticals, Inc.
(AVNR) was a big mover last session, as the company saw its shares
rise by over 6% on the day. The move came on solid volume too with
far more shares changing hands than in a normal session. This
continues the recent uptrend of the company as the stock has now
gained almost 59% since Apr 28.
This drugs manufacturer has seen one positive and one negative
estimate revision over the past 30 days and its Zacks Consensus
Estimate has gone down over the same time frame, suggesting there
may be trouble down the road. So make sure to keep an eye on this
stock going forward to see if this recent move higher can last.
Avanir Pharmaceuticals has a Zacks Rank #2 (Buy) while its Earnings
ESP is positive.
Some better-ranked stocks in the same industry include
Biomerica Inc. (BMRA), Bio-Path Holdings,
Inc. (BPTH) and POZEN Inc. (POZN). All
these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report >>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days. Click
to get this free report
AVANIR PHARM (AVNR): Free Stock Analysis Report
BIOMERICA INC (BMRA): Get Free Report
BIO-PATH HLDGS (BPTH): Get Free Report
POZEN INC (POZN): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research